Further experiments in vivo showed reduced tumor growth in animals subjected to ASOs treatments and these results were associated with impairment of TGF-β-mediated immune suppression (Fitzpatrick et al., 1994; Matthews et al., 2000). The gene discussed is TGFB1; the disease is neoplasm.